Literature DB >> 28504224

Denmark: coronary and structural heart interventions from 2010 to 2015.

Hans-Henrik Tilsted1, Ole Ahlehoff, Christian J Terkelsen, Frants Pedersen, Cengiz Özcan, Troels H Jørgensen, Jens E Nielsen-Kudsk, Jan Ravkilde, Henrik Nissen, Sune A Pedersen, Ole Havndrup, Jens F Lassen.   

Abstract

Interventional cardiology in Denmark has been carried out since the mid 1980s. Interventional cardiology is only performed at a few high-volume centres. Healthcare coverage is universal and is essentially free of charge. Hospitals are mostly publicly owned and financed by fixed budgets and, in part, an activity-based funding system. Approximately 30,000 coronary angiographies (CAG), 10,000 percutaneous coronary interventions (PCIs) of which approximately 25% are primary PCIs, and 500 transcatheter aortic valve implantations (TAVIs) are carried out each year. The numbers of CAG and PCI have reached a plateau in recent years, whereas structural heart interventions, in particular TAVI, are increasing. Around 90% of all patients treated with PCI have a stent implanted, with more than 95% of these being drug-eluting stents. There is a low but increasing use of bioabsorbable scaffolds and drug-eluting balloons.

Entities:  

Mesh:

Year:  2017        PMID: 28504224     DOI: 10.4244/EIJ-D-16-00857

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  2 in total

1.  Diagnostic performance of virtual fractional flow reserve derived from routine coronary angiography using segmentation free reduced order (1-dimensional) flow modelling.

Authors:  Kevin Mohee; Jonathan P Mynard; Gauravsingh Dhunnoo; Rhodri Davies; Perumal Nithiarasu; Julian P Halcox; Daniel R Obaid
Journal:  JRSM Cardiovasc Dis       Date:  2020-11-05

Review 2.  Coronary Angiography With Pressure Wire and Fractional Flow Reserve.

Authors:  Luise Gaede; Helge Möllmann; Tanja Rudolph; Johannes Rieber; Florian Boenner; Monique Tröbs
Journal:  Dtsch Arztebl Int       Date:  2019-03-22       Impact factor: 5.594

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.